Display options
Cite
Daugan M, Murira A, Mindt BC, et al. Type I Interferon Impairs Specific Antibody Responses Early during Establishment of LCMV Infection. Front Immunol. 2016;7:564doi: 10.3389/fimmu.2016.00564.
Daugan, M., Murira, A., Mindt, B. C., Germain, A., Tarrab, E., Lapierre, P., Fritz, J. H., & Lamarre, A. (2016). Type I Interferon Impairs Specific Antibody Responses Early during Establishment of LCMV Infection. Frontiers in immunology, 7564. https://doi.org/10.3389/fimmu.2016.00564
Daugan, Matthieu, et al. "Type I Interferon Impairs Specific Antibody Responses Early during Establishment of LCMV Infection." Frontiers in immunology vol. 7 (2016): 564. doi: https://doi.org/10.3389/fimmu.2016.00564
Daugan M, Murira A, Mindt BC, Germain A, Tarrab E, Lapierre P, Fritz JH, Lamarre A. Type I Interferon Impairs Specific Antibody Responses Early during Establishment of LCMV Infection. Front Immunol. 2016 Dec 05;7:564. doi: 10.3389/fimmu.2016.00564. eCollection 2016. PMID: 27994594; PMCID: PMC5136549.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2016 Dec 05;7:564. doi: 10.3389/fimmu.2016.00564. eCollection 2016.

Type I Interferon Impairs Specific Antibody Responses Early during Establishment of LCMV Infection.

Frontiers in immunology

Matthieu Daugan, Armstrong Murira, Barbara C Mindt, Amélie Germain, Esther Tarrab, Pascal Lapierre, Jörg H Fritz, Alain Lamarre

Affiliations

  1. Immunovirology Laboratory, Institut national de la recherche scientifique (INRS), INRS-Institut Armand-Frappier , Laval, QC , Canada.
  2. Complex Traits Group, Department of Microbiology and Immunology, McGill University , Montréal, QC , Canada.
  3. Complex Traits Group, Department of Microbiology and Immunology, McGill University, Montréal, QC, Canada; Complex Traits Group, Department of Physiology, McGill University, Montréal, QC, Canada.

PMID: 27994594 PMCID: PMC5136549 DOI: 10.3389/fimmu.2016.00564

Abstract

Elicitation of type I interferon (IFN-I) has been shown to both enhance and impair cell-mediated immune responses in acute and persistent viral infections, respectively. Here, we show that, in addition to its effect on T cells, IFN-I drives impairment of specific antibody responses through interaction with B cells in the acute phase of lymphocytic choriomeningitis virus (LCMV) infection. This impairment was limited to the T cell-dependent B cell response and was associated with disruption of B cell follicles, development of hypergammaglobulinemia (HGG), and expansion of the T follicular helper cell population. Antigen-specific antibody responses were restored by ablation of IFN-I signaling through antibody-mediated IFN-I receptor blockade and B cell-specific IFN-I receptor knockout. Importantly, IFN-I receptor deficiency in B cells also accelerated the development of LCMV neutralizing antibodies and alleviated HGG. These results provide a potential therapeutic target toward efficient treatment measures that limit immunopathology in persistent viral infections.

Keywords: LCMV; antibody formation; immunopathology; interferon type I; neutralizing antibodies

References

  1. Int Immunol. 1993 Jun;5(6):647-56 - PubMed
  2. Science. 2013 Apr 12;340(6129):202-7 - PubMed
  3. J Virol. 2006 Apr;80(8):3923-34 - PubMed
  4. J Exp Med. 2004 Nov 1;200(9):1145-56 - PubMed
  5. Nat Immunol. 2004 Sep;5(9):943-52 - PubMed
  6. Nat Immunol. 2006 Mar;7(3):302-10 - PubMed
  7. J Autoimmun. 2013 May;42:19-28 - PubMed
  8. J Immunol. 2007 May 1;178(9):5839-47 - PubMed
  9. J Exp Med. 2010 Jul 5;207(7):1485-500 - PubMed
  10. Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2749-54 - PubMed
  11. Eur J Immunol. 2006 Aug;36(8):2094-105 - PubMed
  12. J Clin Invest. 2004 Oct;114(7):988-93 - PubMed
  13. Science. 2013 Apr 12;340(6129):207-11 - PubMed
  14. Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8252-6 - PubMed
  15. J Immunol. 2007 Mar 15;178(6):3505-10 - PubMed
  16. Int Immunol. 2002 Apr;14(4):411-9 - PubMed
  17. Acta Med Okayama. 1993 Oct;47(5):305-10 - PubMed
  18. J Gastroenterol. 2012 Sep;47(9):1048-56 - PubMed
  19. J Exp Med. 1999 Jun 7;189(11):1791-8 - PubMed
  20. Blood. 2004 Mar 15;103(6):2180-6 - PubMed
  21. J Exp Med. 2001 Feb 5;193(3):297-305 - PubMed
  22. J Immunol. 2006 Apr 1;176(7):3931-41 - PubMed
  23. Nat Protoc. 2008;3(6):1101-8 - PubMed
  24. J Immunol. 1993 Nov 15;151(10):5408-15 - PubMed
  25. J Exp Med. 2012 Dec 17;209(13):2485-99 - PubMed
  26. J Exp Med. 2015 Apr 6;212(4):539-53 - PubMed
  27. J Exp Med. 2008 Aug 4;205(8):1797-805 - PubMed
  28. Immunity. 2001 Apr;14(4):461-70 - PubMed
  29. Nat Med. 2006 Nov;12(11):1301-9 - PubMed
  30. J Virol. 1987 Jun;61(6):1867-74 - PubMed
  31. Nat Immunol. 2010 Jun;11(6):535-42 - PubMed
  32. J Exp Med. 2004 Sep 6;200(5):587-99 - PubMed
  33. Nat Immunol. 2003 Apr;4(4):343-9 - PubMed
  34. J Infect Dis. 2015 Jul 15;212 Suppl 1:S31-6 - PubMed
  35. Nature. 2006 Feb 9;439(7077):682-7 - PubMed
  36. Blood. 2012 Aug 2;120(5):985-93 - PubMed
  37. Adv Immunol. 2016;129:55-107 - PubMed
  38. Nat Rev Immunol. 2015 Feb;15(2):87-103 - PubMed
  39. Cell Host Microbe. 2015 May 13;17(5):653-61 - PubMed
  40. Blood. 2008 Feb 1;111(3):1344-56 - PubMed
  41. J Exp Med. 1985 Dec 1;162(6):2125-41 - PubMed
  42. Proc Natl Acad Sci U S A. 2014 May 20;111(20):7409-14 - PubMed
  43. Immunity. 2013 Nov 14;39(5):912-24 - PubMed
  44. Adv Immunol. 2001;79:1-53 - PubMed
  45. Eur J Immunol. 1985 May;15(5):512-20 - PubMed
  46. J Exp Med. 2000 Oct 2;192(7):931-42 - PubMed
  47. Nat Med. 2013 Apr;19(4):494-9 - PubMed
  48. Cell Host Microbe. 2012 May 17;11(5):481-91 - PubMed
  49. Cell Rep. 2016 Jun 14;15(11):2427-37 - PubMed
  50. Immunity. 2003 Aug;19(2):225-34 - PubMed
  51. J Exp Med. 1991 Dec 1;174(6):1425-9 - PubMed
  52. Vaccine. 2011 Apr 12;29(17):3169-76 - PubMed
  53. J Immunol. 2006 Apr 1;176(7):4343-51 - PubMed
  54. Immunol Rev. 2013 Jul;254(1):207-24 - PubMed
  55. J Virol. 1995 Apr;69(4):2153-8 - PubMed
  56. J Exp Med. 2011 May 9;208(5):987-99 - PubMed

Publication Types